From the beginning to resistance: study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
Subscribe to Our Newsletter
You are leaving this research use-only area
You are about to access content intended for a different region. Information, regulatory status, and product availability may vary by location.
